The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism

Serter R., Demirbas B., Korukluoglu B., Culha C., Cakal E., Aral Y.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, cilt.27, sa.10, ss.897-903, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 10
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1007/bf03347530
  • Dergi Adı: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.897-903
  • Anahtar Kelimeler: subclinical hypothyroidism, thyroxine therapy, lipid profiles, cardiovascular risk, cholesterol, DENSITY-LIPOPROTEIN CHOLESTEROL, THYROID-DISEASE, DOUBLE-BLIND, WOMEN, LEVOTHYROXINE, THYROTROPIN, SPECTRUM, TRIAL, OVERT
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

The aim of our study was to assess the changes in serum lipid profiles after replacement therapy with L-T-4 in patients with subclinical hypothyroidism (SCH), and to see whether there is an improvement in dyslipidemia based cardiovascular risk. Thirty non-smoker pre-menopausal women with newly diagnosed SCH (TSH between 4 and 10 muIU/ml) were involved in our study; twenty-six euthyroid healthy subjects were used as control group. TSH, free T-3 (FT3), free T-4 (FT4), total cholesterol (TC), triglyceride (TG), HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels were measured before and after 6 months of L-T-4 (50-100 mug/day) therapy. TSH levels were targeted as < 2.0 muIU/ml. LDL-C was calculated using the Friede-wald formula, while the cardiovascular risk was assessed with the TC/HDL-C ratio. Pre-treatment serum TC and LDL-C concentrations in SCH patients were significantly higher than those of euthyroid subjects (199.8 +/- 22.2 vs 181.5 +/- 24.6 mg/dl p < 0.01; 146.3 +/- 26.1 vs 124.8 +/- 12 mg/dl, p < 0.001, respectively). TC, LDL-C levels and the TC/HDL-C ratio were reduced significantly after 6-month replacement therapy (-21.1 +/- 34.4 mg/dl or -10.5%, p < 0.01; -21.5 +/- 30.3 mg/dl or -14.7%, p < 0.001, respectively; and TC/HDL-C from 4.8 +/- 0.6 to 4.1 +/- 0.5 mg/dl, p < 0.01), while body mass index (BMI) values did not change. In conclusion, even mild elevations of TSH are associated with changes in lipid profile significant enough to raise the cardiovascular risk ratio, and these changes are corrected once the patients have been rendered euthyroid.